Newsroom

NIH is investing $70 million from the American Rescue Plan to help bring more high-quality, at-home tests onto the market in the U.S. in coordination with the FDA. NIH’s new Independent Test Assessment Program (ITAP) will establish an accelerated pathway to support FDA evaluation of tests with potential for large-scale manufacturing.

NIBIB-funded engineers are using deep learning to differentiate tumor more accurately from normal tissue in positron emission tomography (PET) images.

In Ann Arbor, Mich., as in many other cities across the country, you’d be hard-pressed to find a rapid Covid-19 test today — they’re not available at the nearby Walmart or at local pharmacies. Source:  STAT.

The National Institutes of Health's Rapid Acceleration of Diagnostics initiative announced on Thursday that it has awarded $77.7 million to develop and manufacture 12 new rapid diagnostic tests for SARS-CoV-2. Source: Genomeweb

Detect™, Inc., a Connecticut-based health technology company, announced today that the National Institutes of Health (NIH) has selected the Detect™ Covid-19 Test to receive funding from the highly competitive Rapid Acceleration of Diagnostics Initiative (RADxSM).

The NIH RADx initiative announced today that it has issued contract awards totaling $77.7 million to develop and manufacture 12 new rapid diagnostic tests for SARS-CoV-2, the virus that causes COVID-19. The home and point-of-care testing platforms target the need for high-performance, low-cost home tests and point-of-care tests that can potentially detect multiple respiratory infections.

Johns Hopkins University engineers are the first to use a non-invasive optical probe to understand the complex changes in tumors after immunotherapy, a treatment that harnesses the immune system to fight cancer. Their method combines detailed mapping of the biochemical composition of tumors with machine learning. Source: JHU.

An engineer is reporting fast screening of the surface proteins of exosomes for cancer diagnostics and biomarker discovery.

With a new $1.3 million grant from the NIBIB, researchers led by University of Florida associate professor Zhoumeng Lin are building a tool that can offer drug researchers insight into how well a new nanoparticle-based cancer therapy will work, even before a drug enters animal testing. Source: Nano Magazine.